EU antitrust regulators have asked pharma rivals and customers for feedback in four business areas in light of Novo Holdings' ...

Novo Nordisk chief financial officer Karsten Munk Knudsen said on Wednesday the company was aware of reports of 10 deaths and ...

Correspondent Jon Wertheim revisits 60 Minutes' coverage of former mobile giant Nokia and discusses potential risks for the ...

COPENHAGEN (Reuters) - Novo Nordisk is lifting curbs on prescriptions of its weight-loss drug Wegovy in the United States and is increasing supply in that market, its CEO said on Wednesday.

Compounded versions of semaglutide, the active ingredient in approved diabetes and obesity drugs Ozempic and Wegovy, have ...

The Stoxx Europe 600 Index swelled 1.5% to 517.07. Related NewsInflation Rate YoY for Oct in United States is 2.6%, higher ...

More than two years after a historic Supreme Court decision ended the national right to an abortion, some states are fighting ...

“Honestly, I’m quite alarmed by what we see in the U.S. now,” Novo Nordisk President and CEO Lars Fruergaard ... the demand or projected demand for semaglutide within the United States exceeds the ...

Novo Nordisk (NVO) teased some new details about a potential ... With former President Donald Trump’s election victory, the ...

(Image Credits: Pixabay) Novo Nordisk said on Monday an oral version ... to file for a label expansion for Rybelsus in the United States and the European Union around the turn of the year.

“For example, your company charges $969 in the United States for one month of Ozempic but just $155 in Canada and just $59 in Germany,” Sanders wrote. While Novo Nordisk pushes for a ban on ...